Gilead Sciences Inc
GILD
Company Profile
Business description
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Contact
333 Lakeside Drive
Foster CityCA94404
USAT: +1 650 574-3000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
17,600
Stocks News & Analysis
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks
10 cheap US dividend-growth stocks to buy
The stocks of these companies with a history of dividend increases look undervalued today.
stocks
The 10 best US dividend shares
These undervalued stocks with reliable dividends are worth considering.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,021.90 | 60.20 | 0.76% |
CAC 40 | 7,285.86 | 44.11 | -0.60% |
DAX 40 | 21,205.86 | 105.16 | -0.49% |
Dow JONES (US) | 39,142.23 | 527.16 | -1.33% |
FTSE 100 | 8,275.66 | 0.06 | 0.00% |
HKSE | 21,395.14 | 338.16 | 1.61% |
NASDAQ | 16,286.45 | 20.71 | -0.13% |
Nikkei 225 | 34,730.28 | 352.68 | 1.03% |
NZX 50 Index | 12,118.99 | 51.07 | 0.42% |
S&P 500 | 5,282.70 | 7.00 | 0.13% |
S&P/ASX 200 | 7,819.10 | 60.20 | 0.78% |
SSE Composite Index | 3,280.34 | 4.34 | 0.13% |